Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study

Phase

N/A

Condition

Skin Cancer

Treatment

Educational Intervention

Questionnaire Administration

Dermatoscope

Clinical Study ID

NCT04358276

20096

38249

NCI-2020-01830

20096

Ages > 18
All Genders

Study Summary

This trial studies the impact of a 12-month invention focused on early detection of skin cancer and timely follow up in patients who underwent stem cell transplant and their primary care providers. Some stem cell transplant survivors may develop complications related to the treatment they received. Many of these complications may not be known for years after the treatment and preventive measures can be taken to reduce the chances that a complication will occur and encourage early detection. This study focuses on one complication that stem cell transplant survivors are at high risk of developing - skin cancer. An early diagnosis of skin cancer is important since the cancer is usually smaller, requires less extensive treatments, and has better outcomes. Teaching skin self-examination and encouraging patients to alert doctors to skin changes may provide an important opportunity for early detection of skin cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Have undergone autologous or allogeneic hematopoietic stem cell transplantation (HCT) at City of Hope (COH)
Are 2 years (yrs) to 5 yrs (+/- 3 months [m]) after HCT
Have seen a primary care provider (PCP) in the previous 12 m (expected > 95% of alleligible) or planning to do so in next 12 m
Have a mobile phone with the ability to receive text messages
Can fluently read and write in English or Spanish
Can understand and sign the study-specific Informed Consent Form (ICF)

Exclusion

Exclusion Criteria:

Patients who have evidence of active hematologic malignancy or acute illness thatwould limit study participation

Study Design

Educational Intervention

October 30, 2020

March 31, 2026

Study Description

PRIMARY OBJECTIVES:

I. Determine the impact of patient activation and education (PAE, N=360) alone or with physician activation (PAE+Phys, N=360) on skin cancer screening and health promotion practices at 12 months, measured by percentage of survivors who conduct skin self-exam and receive physician skin exam, and time to detection and diagnosis of suspicious lesions.

II. Among primary care physicians of transplant patients, determine the impact of an e-learning teledermoscopy program compared with provision of print materials for identifying suspect lesions.

OUTLINE: Participants are randomized to 1 of 3 groups.

GROUP I: Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months.

GROUP II: Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit.

GROUP III: Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit. Physicians also receive a free dermatoscope with instructions for uploading images of suspect lesions and attend a 30-minute online course comprising additional descriptions of dermoscopic images for skin cancers and "mimickers" common in hematopoietic stem cell transplantation patients, along with clear instructions for using a dermatoscope and steps to integrate dermoscopy into their practice.

Connect with a study center

City of Hope Medical Center
Duarte, California 91010
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.